What is Histogen?
Histogen Inc. operates at the intersection of biotechnology and regenerative medicine, focusing on the development of first-in-class therapeutics. The company utilizes a sophisticated technology platform that harnesses cell conditioned media and extracellular matrix materials. This methodology is specifically engineered to address a broad spectrum of therapeutic indications, including joint cartilage regeneration, spinal disk repair, and the restoration of tendons and ligaments. By focusing on the body's innate ability to maintain healthy biological function, Histogen distinguishes itself from traditional pharmaceutical approaches, offering targeted solutions that address the root causes of tissue degradation rather than merely managing symptoms.
How much funding has Histogen raised?
Histogen has raised a total of $37.3M across 6 funding rounds:
Private Equity
$9.5M
Private Equity
$6M
Debt
$350K
Share Placement
$10M
Stock Offering
$6.5M
Share Placement
$5M
Private Equity (2007): $9.5M, investors not publicly disclosed
Private Equity (2016): $6M led by Huapont Life Sciences Co.
Debt (2020): $350K supported by PPP
Share Placement (2020): $10M, investors not publicly disclosed
Stock Issuance/Offering (2021): $6.5M, investors not publicly disclosed
Share Placement (2022): $5M, investors not publicly disclosed
Key Investors in Histogen
Huapont Life Sciences Co.
Huapont Life Sciences is a prominent pharmaceutical manufacturer listed on the Shenzhen Stock Exchange, specializing in dermatological, respiratory, and anti-tumor medications with a strong global export footprint.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Histogen?
With the recent influx of $5M, Histogen is well-positioned to accelerate its clinical development programs and refine its manufacturing capabilities. The strategic focus moving forward will likely involve advancing its lead candidates through critical clinical trial phases, thereby validating the efficacy of its hypoxia-induced multipotent cell technology. As the company transitions into more mature stages of development, the emphasis will shift toward commercialization readiness and potential partnerships that can scale its restorative solutions to a global market. Investors and industry observers will be closely monitoring the company's progress in achieving key clinical milestones, which remain the primary catalysts for long-term value creation in the regenerative medicine sector.
See full Histogen company page
